CN104755622B - 用于稳健t细胞和抗体应答的pr13.5启动子 - Google Patents

用于稳健t细胞和抗体应答的pr13.5启动子 Download PDF

Info

Publication number
CN104755622B
CN104755622B CN201380054013.0A CN201380054013A CN104755622B CN 104755622 B CN104755622 B CN 104755622B CN 201380054013 A CN201380054013 A CN 201380054013A CN 104755622 B CN104755622 B CN 104755622B
Authority
CN
China
Prior art keywords
mva
promoter
seq
virus
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380054013.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104755622A (zh
Inventor
罗宾·施泰格瓦尔德
凯·布林克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of CN104755622A publication Critical patent/CN104755622A/zh
Application granted granted Critical
Publication of CN104755622B publication Critical patent/CN104755622B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380054013.0A 2012-10-28 2013-10-28 用于稳健t细胞和抗体应答的pr13.5启动子 Active CN104755622B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719429P 2012-10-28 2012-10-28
US61/719,429 2012-10-28
PCT/EP2013/003239 WO2014063832A1 (en) 2012-10-28 2013-10-28 Pr13.5 promoter for robust t-cell and antibody responses

Publications (2)

Publication Number Publication Date
CN104755622A CN104755622A (zh) 2015-07-01
CN104755622B true CN104755622B (zh) 2021-04-20

Family

ID=49513897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380054013.0A Active CN104755622B (zh) 2012-10-28 2013-10-28 用于稳健t细胞和抗体应答的pr13.5启动子

Country Status (26)

Country Link
US (2) US9828414B2 (enExample)
EP (2) EP3778904A1 (enExample)
JP (2) JP6505016B2 (enExample)
KR (2) KR102135818B1 (enExample)
CN (1) CN104755622B (enExample)
AU (1) AU2013337018B2 (enExample)
BR (1) BR112015009320A2 (enExample)
CA (1) CA2887623C (enExample)
CY (1) CY1123181T1 (enExample)
DK (1) DK2912183T3 (enExample)
EA (2) EA201990114A1 (enExample)
ES (1) ES2800623T3 (enExample)
HK (1) HK1212383A1 (enExample)
HU (1) HUE049706T2 (enExample)
IL (1) IL238130B (enExample)
IN (1) IN2015DN03326A (enExample)
LT (1) LT2912183T (enExample)
MX (2) MX380483B (enExample)
MY (2) MY171687A (enExample)
NZ (1) NZ706637A (enExample)
PT (1) PT2912183T (enExample)
SG (2) SG11201503200PA (enExample)
SI (1) SI2912183T1 (enExample)
UA (1) UA118340C2 (enExample)
WO (1) WO2014063832A1 (enExample)
ZA (1) ZA201502892B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380483B (es) * 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
WO2017129765A1 (en) 2016-01-29 2017-08-03 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
EP3452087A1 (en) * 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
AU2017336269B2 (en) 2016-09-28 2022-06-16 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CA3045228C (en) 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
IL272546B2 (en) 2017-08-24 2024-01-01 Bavarian Nordic As Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody
JP2021506300A (ja) 2017-12-19 2021-02-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物
GB201807932D0 (en) * 2018-05-16 2018-06-27 Redchenko Irina Compositions and methods for inducing an immune response
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CN110904127B (zh) 2018-09-18 2024-09-20 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
IL281988B2 (en) 2018-10-05 2025-03-01 Bavarian Nordic As Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
JP7625518B2 (ja) 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
BR112022009798A2 (pt) 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
US20230233670A1 (en) 2020-06-10 2023-07-27 Bavarian Nordic A/S A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
JP2024535145A (ja) 2021-09-03 2024-09-27 バヴァリアン・ノルディック・アクティーゼルスカブ 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023118563A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12
IL317745A (en) 2022-06-29 2025-02-01 Bavarian Nordic As Modified recombinant SARNA (VRP) and Vaccinia Ankara virus (MVA) prime regimen
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
AU2024208643A1 (en) 2023-01-12 2025-06-26 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
WO2025238221A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Viral vectors encoding multi-antigen-displaying protein nanoparticles
WO2025238219A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Modified vaccinia virus ankara (mva) encoding antigen-displaying protein nanoparticles
WO2025238220A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Nucleic acids for vaccination encoding antigen-displaying protein nanoparticles
WO2025238218A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Viral vectors encoding antigen-displaying protein nanoparticles
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell
FR3171450A1 (fr) 2025-01-17 2026-07-24 Odimma Therapeutics Virus enveloppé pour la transfection d’acides nucléiques exogènes.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1266459A (zh) * 1997-06-09 2000-09-13 奥克松药品有限公司 用于产生cd8t细胞免疫应答的接种方法和试剂
CN1391609A (zh) * 1999-09-21 2003-01-15 埃西斯创新有限公司 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答
WO2006073431A2 (en) * 2004-06-25 2006-07-13 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
JP2008301792A (ja) * 2007-06-11 2008-12-18 National Univ Corp Shizuoka Univ 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法
CA2741724C (en) 2008-11-27 2016-10-04 Bavarian Nordic A/S Promoters for recombinant viral expression
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
MX380483B (es) * 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1266459A (zh) * 1997-06-09 2000-09-13 奥克松药品有限公司 用于产生cd8t细胞免疫应答的接种方法和试剂
CN1391609A (zh) * 1999-09-21 2003-01-15 埃西斯创新有限公司 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答
WO2006073431A2 (en) * 2004-06-25 2006-07-13 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immediate-Early Expression of a Recombinant Antigen by Modified Vaccinia Virus Ankara Breaks the Immunodominance of Strong Vector-Specific B8R Antigen in Acute and Memory CD8 T-Cell Responses;Karen Baur等;《JOURNAL OF VIROLOGY》;20100930;第84卷(第17期);8743-8744 *

Also Published As

Publication number Publication date
JP6818797B2 (ja) 2021-01-20
US20180111966A1 (en) 2018-04-26
LT2912183T (lt) 2020-07-27
SG10201704657WA (en) 2017-07-28
MY171687A (en) 2019-10-23
EP2912183B1 (en) 2020-05-06
KR102135818B1 (ko) 2020-07-22
UA118340C2 (uk) 2019-01-10
JP6505016B2 (ja) 2019-04-24
MX2021001638A (es) 2021-05-12
HUE049706T2 (hu) 2020-10-28
SG11201503200PA (en) 2015-05-28
US20150299267A1 (en) 2015-10-22
EP3778904A1 (en) 2021-02-17
NZ706637A (en) 2019-02-22
IL238130A0 (en) 2015-05-31
EA201990114A1 (ru) 2019-09-30
ZA201502892B (en) 2020-08-26
IL238130B (en) 2019-09-26
ES2800623T3 (es) 2021-01-04
EP2912183A1 (en) 2015-09-02
US11028130B2 (en) 2021-06-08
EA201590831A1 (ru) 2015-08-31
WO2014063832A1 (en) 2014-05-01
DK2912183T3 (da) 2020-07-27
PT2912183T (pt) 2020-06-05
MX380483B (es) 2025-03-12
CA2887623A1 (en) 2014-05-01
KR20200087880A (ko) 2020-07-21
BR112015009320A2 (pt) 2017-10-17
CN104755622A (zh) 2015-07-01
US9828414B2 (en) 2017-11-28
AU2013337018B2 (en) 2019-09-05
AU2013337018A1 (en) 2015-04-30
MX2015005264A (es) 2015-07-17
HK1212383A1 (en) 2016-06-10
IN2015DN03326A (enExample) 2015-10-09
KR20150079596A (ko) 2015-07-08
JP2015533841A (ja) 2015-11-26
CY1123181T1 (el) 2021-10-29
MY194609A (en) 2022-12-06
EA032498B1 (ru) 2019-06-28
CA2887623C (en) 2021-02-16
AU2013337018A9 (en) 2018-08-30
JP2019131572A (ja) 2019-08-08
SI2912183T1 (sl) 2020-07-31

Similar Documents

Publication Publication Date Title
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
US8394385B2 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US10111946B2 (en) Poxviral vectors for low antibody response after a first priming immunization
US9163237B2 (en) Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
AU2017228587B2 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
HK40044708A (en) Pr13.5 promoter for robust t-cell and antibody responses
DK2864487T3 (en) COPPER VIRUS VECTORS TO GET LOW ANTIBODY RESPONSE AFTER A FIRST PRIMING IMMUNIZATION
EA045254B1 (ru) Промотор pr13.5 для устойчивых т-клеточных и гуморальных иммунных реакций
HK1161677B (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant